Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-25-017191
Filing Date
2025-05-15
Accepted
2025-05-15 16:16:04
Documents
57
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q rvph20250331_10q.htm   iXBRL 10-Q 883882
2 EXHIBIT 31.1 ex_818747.htm EX-31.1 9645
3 EXHIBIT 31.2 ex_818748.htm EX-31.2 9551
4 EXHIBIT 32.1 ex_818749.htm EX-32.1 7459
  Complete submission text file 0001437749-25-017191.txt   4700349

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA rvph-20250331.xsd EX-101.SCH 44988
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvph-20250331_def.xml EX-101.DEF 277920
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvph-20250331_lab.xml EX-101.LAB 241860
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvph-20250331_pre.xml EX-101.PRE 305224
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rvph-20250331_cal.xml EX-101.CAL 23608
60 EXTRACTED XBRL INSTANCE DOCUMENT rvph20250331_10q_htm.xml XML 746485
Mailing Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014
Business Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014 4085018881
REVIVA PHARMACEUTICALS HOLDINGS, INC. (Filer) CIK: 0001742927 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38634 | Film No.: 25953409
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)